About
The Winslow philosophy
Company background
Our associates
Careers at Winslow
News
Commentary library
Philanthropy at Winslow
Spotlight on Winslow
Contact
Contact us
Contact associates
Directions – Boston
Directions – Braintree, MA
Directions – New York City
Directions – Paramus, NJ
Account Login
Account Resources
How-to: Access my account
Cybersecurity
Tax Center
Tax Form Downloads to TurboTax®
Important information for investors
NetXInvestor™ App
Money market sweeps
INDIVIDUAL INVESTORS
+ What approach is right for me?
+ Choosing a financial professional
+ Brokers
+ Investment advisors
+ The Winslow philosophy
+ Plan for life
+ What to expect: Six steps
+ Plan for retirement
+ Save for college
+ Invest and trade
+ Tax-advantaged investing
+ Trading desk services
+ Client support
+ Insure your future
+ Life insurance
+ Annuities: “Income for life”
+ Property and casualty
+ Submit your current policy
+ Long-term care
INSTITUTIONAL INVESTORS
+ Equity trading
+ Fixed income
+ Municipal desk
FIND AN ADVISOR
+ by Name
+ by Branch
OPPORTUNITIES AT WINSLOW
+ Financial advisors
+ Business partners
+ Working with Winslow
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Biovie Inc
(NQ:
BIVI
)
37.17
+7.23 (+24.15%)
Streaming Delayed Price
Updated: 3:14 PM EST, Jan 15, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Biovie Inc
BioVie Interview to Air on Bloomberg International on the RedChip Money Report
October 30, 2020
From
GlobeNewswire News Releases
BioVie to Participate in B. Riley Securities Liver Disease Therapeutics Day on October 29, 2020
October 29, 2020
From
GlobeNewswire News Releases
BioVie Announces Closing of Public Offering of Common Stock
September 23, 2020
Includes Full Exercise of Underwriters’ Overallotment Option
From
GlobeNewswire News Releases
BioVie to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit
September 21, 2020
From
ACCESSWIRE
Highly Accomplished Executives Join BioVie’s Board of Directors
June 16, 2020
From
GlobeNewswire News Releases
BioVie Advances the BIV201 Clinical Program and Prefilled Syringe
June 11, 2020
From
GlobeNewswire News Releases
BioVie Submits Protocol for Phase 2b/3 Refractory Ascites Study to FDA
October 22, 2019
From
ACCESSWIRE
BriaCell Appoints Richard J. Berman to Board of Directors
August 12, 2019
From
GlobeNewswire News Releases
BioVie Achieves Primary Objectives in Phase 2a Clinical Trial of BIV201 in Refractory Ascites
April 30, 2019
BioVie Inc. (OTCQB: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, today announced top-line results for its Phase 2a clinical trial of...
From
GlobeNewswire News Releases
BioVie to Present at ThinkEquity Conference in NYC on May 2nd
April 24, 2019
BioVie Inc. (OTCQB: BIVI) (“BioVie” or “Company”), a clinical-stage company developing innovative drug therapies for liver disease, announced that Mr. Terren Peizer, the Company’s Chairman and CEO, is...
From
GlobeNewswire News Releases
BioVie Completes Patient Enrollment for its Phase 2a Clinical Trial of BIV201 in Refractory Ascites
February 06, 2019
BioVie Inc. (OTCQB: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for liver disease, announced today that it has completed enrollment in a Phase 2a...
From
GlobeNewswire News Releases
BioVie’s New Drug Candidate BIV201 Receives FDA Orphan Drug Designation for the Treatment of Hepatorenal Syndrome (HRS)
November 27, 2018
From
ACCESSWIRE
Veterinary Vaccines Market Opportunity by 2026 : Merial, Zoetis, Elanco, Merck & Co. Inc., Boehringer Ingelheim GmbH)(BIVI), Bayer Pharma AG
October 30, 2018
Valley Cottage, NY -- (SBWIRE) -- 10/30/2018 -- Increasing focus on maintaining the reproductive health of livestock is expected to generate significant demand for livestock veterinary vaccines, finds...
From
SBWire - Latest Press Releases
BioVie Inc. (OTCQB:BIVI) Attains Milestone
April 09, 2018
Company Reaches 50% Patient Enrollment in Phase 2a Clinical Trial of BIV201 for Refractory Ascites
From
GlobeNewswire News Releases
BioVie to Present at The MicroCap Conference in New York on April 9th
March 22, 2018
BioVie Inc. (OTCQB:BIVI), a clinical-stage company focused on the development and commercialization of innovative drug therapies for liver disease, announced today that it will participate in The...
From
GlobeNewswire News Releases
BioVie Responds to Japan Patent Office and Comments on Recent Stock Price Decline
March 06, 2018
BioVie Inc. (OTCQB:BIVI), a clinical-stage company focused on the development and commercialization of innovative drug therapies for liver disease, announced today that it submitted a response to...
From
GlobeNewswire News Releases
BioVie Receives FDA Fast Track Designation for BIV201 for the Treatment of Refractory Ascites Due to Advanced Liver Cirrhosis
December 10, 2017
From
Marketwired News Releases
BioVie Announces Second Patient Dosed with BIV201 in Phase 2a Clinical Trial; First Patient Completes 28-day Treatment Regimen
November 07, 2017
From
Marketwired News Releases
Accomplished BioPharma Executive Mina Sooch Joins BioVie Board of Directors and Purchases Company Stock
November 02, 2017
From
Marketwired News Releases
Michael Sherman Joins BioVie Board of Directors and Purchases Company Stock
October 25, 2017
From
Marketwired News Releases
BioVie Announces First Patient Dosed with BIV201 in Phase 2a Clinical Trial for Refractory Ascites due to Liver Cirrhosis
September 28, 2017
From
Marketwired News Releases
Rich Wieland Joins BioVie Management Team as Chief Financial Officer
September 25, 2017
From
Marketwired News Releases
CORRECTION - BioVie Inc.
September 14, 2017
From
Marketwired News Releases
First Patent Enrolled in BioVie Phase 2a Clinical Trial of BIV201 for Ascites
September 14, 2017
From
Marketwired News Releases
BioVie Reports Fiscal Year 2017 Financial Results and Clinical Development Progress
August 29, 2017
From
Marketwired News Releases
BioVie Files Patent Application in Japan for BIV201 for the Treatment of Ascites Due to Liver Cirrhosis
July 26, 2017
From
Marketwired News Releases
BioVie Inc. to Present at the 7th Annual LD Micro Invitational
May 26, 2017
From
ACCESSWIRE
BioVie Announces Issuance of US Patent Covering BIV201 for the Treatment of Ascites Due to Liver Cirrhosis
May 24, 2017
From
Marketwired News Releases
Distinguished BioPharma Executive Hari Kumar Joins BioVie Board of Directors and Purchases Company Stock
May 10, 2017
From
Marketwired News Releases
BioVie Signs Cooperative Research and Development Agreement (CRADA) to Conduct a Phase 2a Clinical Trial of BIV201 in Refractory Ascites Patients
April 25, 2017
From
Marketwired News Releases
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Market Action
Symbol Lookup
MARKET NEWS